Quick Answer
Voyager Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $40.37 million for the year ending 2025.
- Voyager Therapeutics, Inc. showed a decrease of -49.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Voyager Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 183.9%.
- Historical annual values: Fiscal year 2025: $40.37 million | Fiscal year 2024: $80.00 million | Fiscal year 2023: $250.01 million | Fiscal year 2022: $40.91 million | Fiscal year 2021: $37.42 million | Fiscal year 2020: $171.13 million | Fiscal year 2019: $104.39 million | Fiscal year 2018: $7.62 million | Fiscal year 2017: $10.14 million | Fiscal year 2016: $14.22 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: